FI954383A - Menetelmä syöpärokotteiden valmistamiseksi - Google Patents
Menetelmä syöpärokotteiden valmistamiseksi Download PDFInfo
- Publication number
- FI954383A FI954383A FI954383A FI954383A FI954383A FI 954383 A FI954383 A FI 954383A FI 954383 A FI954383 A FI 954383A FI 954383 A FI954383 A FI 954383A FI 954383 A FI954383 A FI 954383A
- Authority
- FI
- Finland
- Prior art keywords
- preparation
- cancer vaccines
- vaccines
- cancer
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0055693A AT399656B (de) | 1993-03-19 | 1993-03-19 | Verfahren zur herstellung von krebsvakzinen |
DE4326821A DE4326821A1 (de) | 1993-08-10 | 1993-08-10 | Verfahren zur Herstellung von Krebsvakzinen |
PCT/EP1994/000859 WO1994021808A1 (de) | 1993-03-19 | 1994-03-18 | Verfahren zur herstellung von krebsvakzinen |
Publications (2)
Publication Number | Publication Date |
---|---|
FI954383A true FI954383A (fi) | 1995-09-18 |
FI954383A0 FI954383A0 (fi) | 1995-09-18 |
Family
ID=25593140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI954383A FI954383A0 (fi) | 1993-03-19 | 1995-09-18 | Menetelmä syöpärokotteiden valmistamiseksi |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0689604A1 (de) |
JP (1) | JPH08507921A (de) |
KR (1) | KR960701211A (de) |
CN (1) | CN1119459A (de) |
AU (1) | AU6427994A (de) |
CA (1) | CA2158655A1 (de) |
CZ (1) | CZ241795A3 (de) |
FI (1) | FI954383A0 (de) |
HU (1) | HUT73383A (de) |
NO (1) | NO953684D0 (de) |
NZ (1) | NZ263550A (de) |
PL (1) | PL311036A1 (de) |
WO (1) | WO1994021808A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69535288T2 (de) * | 1994-05-13 | 2007-04-05 | Thomas Jefferson University | Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren |
US6093700A (en) | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
DE4426429A1 (de) * | 1994-07-26 | 1996-02-01 | Boehringer Ingelheim Int | Verfahren zum Einführen von DNA in höhere eukaryotische Zellen |
DE19510344C1 (de) * | 1995-03-22 | 1996-11-07 | Boehringer Ingelheim Int | Verwendung einer Tumorvakzine |
EP0835130A1 (de) * | 1995-06-19 | 1998-04-15 | University Of Medicine & Dentistry Of New Jersey | Gentherapie von soliden tumoren mit interferone allein oder mit anderen immunoeffektoren proteinen |
DE19608751B4 (de) | 1996-03-06 | 2006-05-18 | Medigene Ag | Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen |
DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
DE19631357A1 (de) * | 1996-08-02 | 1998-02-05 | Deutsches Krebsforsch | Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen |
ES2167939T3 (es) | 1997-08-13 | 2002-05-16 | Biontex Lab Gmbh | Nuevas poliaminas, su preparacion y usos. |
CN100352511C (zh) * | 1997-08-13 | 2007-12-05 | Uab研究基金会 | 局部应用基因载体的疫苗接种 |
US7348015B2 (en) | 1998-01-14 | 2008-03-25 | Morphogenesis, Inc. | Antigen modified cancer cell vaccines for cancer therapy |
WO1999036433A2 (en) | 1998-01-14 | 1999-07-22 | Morphogenesis, Inc. | Materials and methods for treating oncological disease |
US7795020B2 (en) | 1998-01-14 | 2010-09-14 | Morphogenesis, Inc. | Tumor cell vaccines |
WO1999042121A1 (en) | 1998-02-20 | 1999-08-26 | University Of Miami | Modified heat shock protein-antigenic peptide complex |
ATE407695T1 (de) * | 1999-02-09 | 2008-09-15 | Riken | Tumorimpfstoff |
BR0001029A (pt) * | 2000-04-10 | 2001-11-20 | Fk Biotecnologia Ltda | Processo de transformação de células tumorais |
AUPQ755300A0 (en) * | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
DE10131148A1 (de) * | 2001-06-28 | 2003-01-16 | I P L Internat Pharmaceutics L | Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren |
US7176022B2 (en) | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
CN102014937A (zh) | 2008-03-03 | 2011-04-13 | 迈阿密大学 | 基于异基因癌细胞的免疫治疗 |
EP2274001A4 (de) | 2008-03-20 | 2012-08-01 | Univ Miami | Impfung mit hitzeschockprotein gp96 und anwendungsverfahren dafür |
AU2011336019B2 (en) * | 2010-12-02 | 2016-07-07 | Oncotherapy Science, Inc. | TOMM34 peptides and vaccines including the same |
KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
AU2017304219A1 (en) * | 2016-07-25 | 2019-02-21 | Ascend Biopharmaceuticals Ltd | Methods of treating cancer |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
US20210054332A1 (en) * | 2017-12-29 | 2021-02-25 | Genemedicine Co., Ltd | Cell sheet for gene delivery |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
-
1994
- 1994-03-18 CZ CZ952417A patent/CZ241795A3/cs unknown
- 1994-03-18 WO PCT/EP1994/000859 patent/WO1994021808A1/de not_active Application Discontinuation
- 1994-03-18 JP JP6520658A patent/JPH08507921A/ja active Pending
- 1994-03-18 HU HU9502720A patent/HUT73383A/hu unknown
- 1994-03-18 NZ NZ263550A patent/NZ263550A/en unknown
- 1994-03-18 CN CN94191520A patent/CN1119459A/zh active Pending
- 1994-03-18 CA CA002158655A patent/CA2158655A1/en not_active Abandoned
- 1994-03-18 PL PL94311036A patent/PL311036A1/xx unknown
- 1994-03-18 AU AU64279/94A patent/AU6427994A/en not_active Abandoned
- 1994-03-18 EP EP94911921A patent/EP0689604A1/de not_active Withdrawn
-
1995
- 1995-08-28 KR KR1019950703645A patent/KR960701211A/ko not_active Application Discontinuation
- 1995-09-18 NO NO953684A patent/NO953684D0/no unknown
- 1995-09-18 FI FI954383A patent/FI954383A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
PL311036A1 (en) | 1996-01-22 |
WO1994021808A1 (de) | 1994-09-29 |
JPH08507921A (ja) | 1996-08-27 |
CA2158655A1 (en) | 1994-09-29 |
KR960701211A (ko) | 1996-02-24 |
AU6427994A (en) | 1994-10-11 |
FI954383A0 (fi) | 1995-09-18 |
EP0689604A1 (de) | 1996-01-03 |
NO953684L (no) | 1995-09-18 |
NZ263550A (en) | 1996-12-20 |
HU9502720D0 (en) | 1995-11-28 |
HUT73383A (en) | 1996-07-29 |
CZ241795A3 (en) | 1996-04-17 |
NO953684D0 (no) | 1995-09-18 |
CN1119459A (zh) | 1996-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI954383A (fi) | Menetelmä syöpärokotteiden valmistamiseksi | |
FI103967B1 (fi) | Menetelmä tetrahydrokarbatsonijohdannaisten valmistamiseksi | |
FI945441A (fi) | Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmistamiseksi | |
FI960278A (fi) | Anataasititaanidioksidin valmistusmenetelmä | |
FI103666B1 (fi) | Menetelmä bifenyylijohdannaisen valmistamiseksi | |
FI962370A (fi) | Laite tissuen valmistamiseksi | |
FI892058A0 (fi) | Fenolin valmistusmenetelmä | |
FI940769A (fi) | Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi | |
FI952585A0 (fi) | Menetelmä bentsopyraaniyhdisteiden valmistamiseksi | |
FI942907A (fi) | Menetelmä lipaasin valmistamiseksi | |
FI954272A (fi) | Menetelmä akryylipiperidiinikarbinolien valmistamiseksi | |
FI960254A (fi) | Menetelmä N-(4-hydroksifenyyli)-retiiniamidin valmistamiseksi | |
FI902316A0 (fi) | Menetelmä valmistaa terapeuttisesti vaikuttavia substituoituja dihydropyrrolitsiiniyhdisteitä | |
FI102270B1 (fi) | Menetelmä dieettereiden valmistamiseksi | |
FI942102A (fi) | Menetelmä alumiinioksaanien valmistamiseksi | |
FI964229A0 (fi) | Menetelmä doksorubisiinin valmistamiseksi | |
FI911701A (fi) | Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi | |
NO941056D0 (no) | Fremgangsmåte for fremstilling av organoklorsilaner | |
FI956058A (fi) | Menetelmä glutaaridialdehydin valmistamiseksi | |
FI942394A0 (fi) | Menetelmä steroidiperasyyliglykosidien valmistamiseksi | |
FI961178A (fi) | Menetelmä syklisten cis-1-amino-2-alkanolien valmistamiseksi | |
FI892144A0 (fi) | Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi | |
FI102841B1 (fi) | Menetelmä mannitolin valmistamiseksi | |
FI940551A (fi) | Menetelmä fenyylibentsamidijohdannaisten valmistamiseksi | |
FI971964A0 (fi) | Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi |